Arvinas (ARVN) Shares Outstanding (2017 - 2026)
Arvinas (ARVN) posted quarterly Shares Outstanding (Entity) of $74.5 million for Q1 2026, up 2.05% year-over-year from $73.0 million in Q1 2025, and up 1.36% quarter-over-quarter from $73.5 million in Q4 2025.
Arvinas (ARVN) Shares Outstanding (2017 - 2026) Analysis & Trends
Arvinas' Shares Outstanding (Entity) history runs 10 years deep, the most recent figure standing at $74.5 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 2.05% year-over-year to $74.5 million; the TTM figure through Mar 2026 stood at $74.5 million (up 2.05% YoY), while the FY2025 annual figure was $73.5 million, up 6.83% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $74.5 million, up from $73.5 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $74.5 million in Q1 2026, with the low at $53.1 million in Q1 2022.
- The 5-year median for Shares Outstanding (Entity) is $68.3 million (2024), against an average of $63.1 million.
- The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Entity) gained 0.38% in 2023, then grew 28.46% in 2024.
- Arvinas' Shares Outstanding (Entity) stood at $53.2 million in 2022, then climbed by 4.32% to $55.5 million in 2023, then advanced by 23.96% to $68.8 million in 2024, then grew by 6.83% to $73.5 million in 2025, then increased by 1.36% to $74.5 million in 2026.
- Business Quant data shows ARVN's Shares Outstanding (Entity) at $74.5 million in Q1 2026, $73.5 million in Q4 2025, and $73.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Arvinas | 585.74 Mn | 17.84 Mn | - | 64.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 64.80 Mn |
| Mar 31, 2026 | 64.00 Mn |
| Dec 31, 2025 | 70.90 Mn |
| Sep 30, 2025 | 73.20 Mn |
| Jun 30, 2025 | 73.00 Mn |
| Mar 31, 2025 | 72.50 Mn |
| Dec 31, 2024 | 71.90 Mn |
| Sep 30, 2024 | 72.10 Mn |
| Jun 30, 2024 | 71.90 Mn |
| Mar 31, 2024 | 71.70 Mn |
| Dec 31, 2023 | 55.50 Mn |
| Sep 30, 2023 | 54.10 Mn |
| Jun 30, 2023 | 53.40 Mn |
| Mar 31, 2023 | 53.30 Mn |
| Dec 31, 2022 | 53.20 Mn |
| Sep 30, 2022 | 53.20 Mn |
| Jun 30, 2022 | 53.20 Mn |
| Mar 31, 2022 | 53.00 Mn |
| Dec 31, 2021 | 50.00 Mn |
| Sep 30, 2021 | 49.81 Mn |